• Kemal Özyurt, Gökmen Zararsız, Ragıp Ertaş, Ahu Cephe, Ömer Kutlu, Ömer Faruk Elmas, Muhammed Reşat Akkuş, Fatma Nur Kutlu, and Mustafa Atasoy.
• Department of Dermatology and Venereology, Medicine Faculty, Ahi Evran University, Kırşehir, Turkey.
• Turk J Med Sci. 2022 Feb 1; 52 (1): 586658-66.

BackgroundTPSORTAKSIS is a psoriasis registry, which is used for follow-up of patients in Kayseri City Education and Research Hospital, Dermatology Clinic since 2016 in Turkey. PSORTAKSIS includes demographic data, follow-up clinical findings, laboratory output, and treatment information of patients. Here, drug survivals of biologic therapeutics (BT) according to three-year data of PSORTAKSIS will be presented.MethodsDrug survival of BT in PSORTAKSIS was analyzed from 2016 to March 2019.Results158 patients (111 of them BT-naive) with psoriasis under BT were enrolled in the current study. Drug survival analysis of patients with ongoing BT (158 treatment periods) revealed mean survival time as 15.49 months for ustekinumab, 15.37 months for adalimumab, 14.00 months for etanercept, 5 months for infliximab, and 4.59 months for secukinumab. The differences between drug survivals of BT were statistically significant (log-rank test, χ2 = 79.915, p < 0.0001).

14 keywords...

hide…